Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 10/20 | 0.57 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050414 | 0.91 | ZAP70 (0.67) | ZAP70EGFRMAP4K1 | |
| SCHEMBL1048431 | 0.90 | ZAP70 (0.62) | ZAP70EGFR | |
| SCHEMBL1068637 | 0.84 | ZAP70 (0.68) | ZAP70EGFRJAK2 | |
| SCHEMBL12960916 | 0.84 | ZAP70 (0.65) | ZAP70EGFRMAP4K1 | |
| SCHEMBL12961007 | 0.84 | ZAP70 (0.80) | ZAP70JAK2JAK3 | |
| SCHEMBL12928819 | 0.81 | ZAP70 (0.84) | ZAP70EGFR | |
| SCHEMBL1049985 | 0.81 | ZAP70 (0.76) | ZAP70JAK2 | |
| SCHEMBL1046635 | 0.79 | ZAP70 (0.70) | ZAP70EGFRMAP4K1JAK1 | |
| SCHEMBL1048717 | 0.78 | ZAP70 (0.67) | ZAP70EGFR | |
| SCHEMBL1048551 | 0.76 | ZAP70 (0.80) | ZAP70EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885EGFR 237/4885NSD2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.